每经记者｜金喆 每经编辑｜董兴生 9月12日，药捷安康-B（02617.HK）用最高超130%、单日上涨77.09%的涨幅，诠释了当下港股创新药 板块的疯狂。截至当日收盘，药捷安康总市值达到764亿港元，排在港股创新药板块第12位。药捷安康 也是今年港股创新药概念股中唯一的"十倍股"，6月23日挂牌上市以来，在不到3个月时间里股价涨幅达 到1363.88%。 药捷安康作为一家2014年成立的创新药企，主要从事小分子创新药研发，暂无产品获批上市，过去三年 累计亏损8.7亿元。公司股价近期的上涨，起始于9月10日披露核心产品替恩戈替尼一项临床试验获得临 床默示许可的公告，此后3个交易日，市值激增近480亿港元。 一款产品从二期临床试验到获批上市，需要经历多个关键节点，药捷安康的"临床故事"真有这么高的含 金量吗？ 一则公告拉动480亿港元市值？业内人士：太夸张了 9月10日，药捷安康发布公告称，公司核心产品替恩戈替尼联合氟维司群治疗经治失败的激素受体阳性 （HR+）且人表皮生长因子受体2阴性或低表达（HER2-）的复发或转移性乳腺癌II期临床试验，已于 2025年9月10日获得国家药品监督管理局的临床默示许可。 ...

Core Viewpoint - The market is experiencing a favorable sentiment with expectations of interest rate cuts in the U.S. and a return to previous high points in the domestic market [1] Group 1: Market Outlook - Inflation remains stable overseas, coupled with weak non-farm payrolls, leading to sustained expectations for interest rate cuts, with predictions of a cut in September and three cuts within the year [1] - The long-term market trend is supported by multiple favorable factors including proactive policies, industry catalysts, overseas monetary easing, and new capital inflows [1] - Short-term catalysts include Oracle's orders reflecting demand for computing power and the anticipated interest rate cut by the Federal Reserve next week [1] Group 2: Investment Strategy - The bull market is not over, despite increased market volatility, as leading stocks have not been abandoned [1] - The investment strategy focuses on technology and cyclical sectors, with a particular emphasis on gold, which has started to perform well due to the Federal Reserve's changing stance and weakening employment [1] - Attention is also directed towards the resurgence of innovative drug enthusiasm and the expansion of AI trends, while valuing leading internet and AI application stocks with low congestion [1] Group 3: Economic Context - The overseas economic cycle is nearing a bottom, while domestic efforts to reduce internal competition continue to advance, highlighting the value of leading cyclical resource stocks [1]

Group 1: Company Overview - Company name:劲方医药-B, established in 2017, focuses on innovative drug development for oncology, autoimmune, and inflammatory diseases [8][10] - The company has a product pipeline consisting of 8 candidate products, with 5 in clinical development, including core products GFH925 and GFH375 [10][12] - GFH925 is the first KRAS G12C inhibitor approved for commercialization in China, while GFH375 is a KRAS G12D inhibitor currently in clinical trials [12][16] Group 2: IPO Details - The IPO is scheduled from September 11 to September 16, with a listing date on September 19, at a price of HKD 20.39 per share [3][4] - The total fundraising amount is HKD 15.82 billion, with a total issuance of 77,600,000 shares, of which 10% is for public offering and 90% for international placement [3][4] - The company has a strong cornerstone investor base, with 9 investors committing USD 100 million, accounting for 49.27% of the total issuance [5] Group 3: Financial Performance - Revenue for 2023, 2024, and the first four months of 2025 is projected at RMB 73.74 million, RMB 104.70 million, and RMB 82.15 million respectively [18][22] - The company has been operating at a loss, with net profits of -RMB 508.32 million, -RMB 677.64 million, and -RMB 66.62 million for the respective periods [19][22] - As of April 30, 2025, the company has cash reserves of RMB 391 million [21] Group 4: Market and Competitive Landscape - The global KRAS G12C inhibitor market is expected to grow from USD 489 million in 2024 to USD 3.491 billion by 2033, with a compound annual growth rate of 24.4% [13][16] - The competitive landscape includes several approved KRAS G12C inhibitors, with GFH925 being the first in China and competing against products from major pharmaceutical companies [16] - The company aims to expand its product pipeline beyond RAS drugs, including candidates like GFS202A, a bispecific antibody targeting GDF15 and IL-6 [16][17]

Investment Rating - Investment rating: Positive (maintained) [4] Core Viewpoints - The report emphasizes the potential of PD1/VEGF/IL-2 mechanisms and suggests continued attention on Shanghai Yizhong [3][4] - The Chinese pharmaceutical industry has completed the transition from old to new growth drivers, with innovative drugs significantly opening new growth curves for Chinese pharmaceutical companies [51][52] - The report highlights the importance of innovation in the pharmaceutical sector, with a focus on the growth of innovative drugs and the increasing ability of Chinese companies to expand internationally [51][52] Summary by Sections Market Performance - From September 8 to September 12, the pharmaceutical index rose by 1.03%, outperforming the CSI 300 index by 0.47% [5] - The number of stocks that rose this week was 263, while 220 stocks fell, with the top gainers being Zhend Medical (+41%) and Haooubo (+28%) [5][35] Investment Opportunities - Suggested stocks to watch include: 1) Innovative drugs: Xinlitai, Rejing Bio, Shanghai Yizhong, Kanghong Pharmaceutical, and others [5] 2) Companies with improving performance and low valuation: WuXi AppTec, Tigermed, and others [5] 3) Medical consumables and drug companies benefiting from marginal improvements in centralized procurement [5] Mechanism Insights - The report discusses the complementary mechanisms of PD1, VEGF, and IL-2, highlighting Shanghai Yizhong's YXC-001, which integrates these three targets into a single molecule, potentially offering significant advantages in efficacy and pharmacokinetics [3][30][34] Industry Trends - The report notes that the aging population and chronic disease demand are increasing, with a focus on cardiovascular, endocrine, and orthopedic diseases [51] - The payment side is also improving, with steady growth in medical insurance revenue and the promotion of commercial insurance [51] Future Outlook - The report anticipates a rebound in the pharmaceutical industry in 2025, driven by innovative drugs, with structural growth expected in specific sectors and stocks [51][52] - It suggests that the second half of 2025 will see a recovery in medical consumption and manufacturing performance, with a focus on low-valuation assets [52]

Core Viewpoint - The A-share market has shown strong performance in 2025, with significant increases in major indices, leading to impressive returns for equity-focused public funds [3][4]. Group 1: Market Performance - As of September 10, 2025, the Shanghai Composite Index has risen approximately 13.74% year-to-date, while the Shenzhen Component Index and the ChiNext Index have increased by about 20.58% and 35.61%, respectively [3]. - The average return for equity mixed funds is 27.49%, and for ordinary stock funds, it is 27.43% as of September 9, 2025 [3]. Group 2: Fund Manager Rankings - There are 1,630 fund managers whose managed funds have over 80% of their net asset value in stock investments, with a total management scale exceeding 8.07 trillion yuan [4]. - The top five fund managers based on performance this year are Ren Jie from Yongying Fund, Leng Wenpeng from CITIC Construction Investment Fund, Liang Furui from Changcheng Fund, Han Hao from AVIC Fund, and Tang Chen from Nuoan Fund, with returns ranging from 104.96% to 170.58% [4][5]. Group 3: Notable Fund Managers - Ren Jie leads the rankings with a return of 170.58% for the year, managing two funds with a total scale of approximately 1.166 billion yuan [11]. - Zhang Wei from Huatai-PB Fund is among the three fund managers managing over 10 billion yuan, achieving a return of 75.34% this year [15]. Group 4: Investment Insights - Ren Jie emphasizes the growth of AI applications and the potential for companies in optical communication and PCB sectors to benefit from global AI development [12]. - Zhang Wei highlights the ongoing recovery in the pharmaceutical sector, with a focus on innovative drugs and the expected growth in the Chinese pharmaceutical market [16].

Group 1 - The core viewpoint of the article emphasizes the routine patrols conducted by the Southern Theater Command of the People's Liberation Army in the South China Sea from September 12 to 13, asserting China's commitment to safeguarding national sovereignty and regional stability [1] - The article highlights the Philippines' attempts to engage external forces for joint patrols, which are viewed as efforts to undermine peace and stability in the region [1] - The Southern Theater Command warns the Philippines to cease provocations and escalations in the South China Sea, indicating that any attempts to disrupt the situation will be futile [1]

Core Viewpoint - The innovative drug sector has shown strong performance this year, bringing the pharmaceutical industry back into the spotlight, with a focus on the potential for significant growth in the coming years [1][4]. Group 1: Fund Management and Strategy - The "Oriental Red Medical Innovation Mixed Fund" is managed by experienced professionals, including Jiang Qi, who has a strong background in both buy-side and sell-side research [1]. - Jiang Qi employs a "combination" strategy in the pharmaceutical sector, focusing on growth stocks, undervalued transformation targets, blue-chip stocks, and companies with stable cash flow, adjusting asset allocation based on market conditions [1][5]. Group 2: Performance and Future Outlook - The "Oriental Red Medical Upgrade Stock Initiation Fund" has demonstrated significant excess returns since its inception, with an A-class share net value growth rate of 71.72% compared to a benchmark decline of 6.17% [2]. - Jiang Qi believes that the innovative drug sector is at the beginning of a rapid growth phase, with many companies expected to transition from losses to profitability in the next five years [2][4]. Group 3: Market Dynamics and Investment Opportunities - The innovative drug industry is anticipated to enter a phase of explosive growth, with 2025 seen as a pivotal year for capital market developments [4]. - Despite the strong performance of innovative drugs, the overall market allocation to this sector remains limited, indicating that excess returns are likely to persist [5][6]. Group 4: Long-term Growth and Challenges - The pharmaceutical industry is characterized by its "long slope, thick snow" nature, where new growth points can be identified at any time, driven by technological advancements [7]. - The development of commercial insurance is expected to positively impact the innovative drug sector by allowing for better pricing and extending product life cycles [7]. Group 5: Technological Impact and Market Trends - AI applications in the pharmaceutical industry are primarily focused on drug discovery and development, with the potential for significant long-term benefits [8]. - The performance of innovative drug stocks in the Hong Kong market has outpaced that in the A-share market, largely due to differences in market liquidity rather than company quality [8][9]. Group 6: Investment Philosophy and Patience - Jiang Qi emphasizes the importance of patience in holding investments in innovative drugs, as the sector is expected to undergo substantial changes driven by fundamental developments [10][12]. - The focus should be on identifying companies with solid fundamentals and the potential for global clinical operations, as these will likely yield significant returns in the long run [10][11].

Group 1 - The core theme of the series of activities initiated by the Beijing Securities Association is "New Era, New Fund, New Value," aimed at promoting high-quality development in the public fund industry [2] - The 2025 China International Service Trade Fair emphasizes the importance of technology finance in modernizing the economy, with a focus on financial services for the real economy [2] - Zhongjia Fund was awarded the title of "Best Cooperation Partner in Financial Services" at the service trade fair, highlighting its strategic alignment with the Beijing Bank Group [2] Group 2 - As a subsidiary of Beijing Bank, Zhongjia Fund aims to create a brand of "Specialized, Refined, Unique, and Innovative First Fund" to provide lifelong fund services to investors [3] - A technology finance investment strategy sharing session was held, featuring insights from fund managers on the growth potential of technology stocks, particularly in AI, chips, communications, and innovative pharmaceuticals [3] - Zhongjia Fund is committed to focusing on the "Five Major Articles" of finance, supporting the growth of quality technology enterprises, and seizing opportunities presented by technological innovation [3]

Core Viewpoint - The article highlights the increasing prominence of female fund managers in the public fund industry, showcasing their performance and contributions to the sector as their representation grows [3][4]. Summary by Sections Female Fund Managers Overview - As of September 9, 2025, there are 3,868 active public fund managers, with 2,831 males (73.19%) and 1,037 females (26.81%) [3]. Performance of Female Fund Managers - The threshold for the top 10 female fund managers with over 10 years of experience this year is a return of 29.65% [4]. - Among these top performers, two managers from Ping An Fund achieved the highest returns [4]. Top Performing Female Fund Managers - The top female fund manager is Zhou Encong from Ping An Fund, with a return of 90.02% and a management scale exceeding 30 billion yuan [5][6]. - Other notable managers include Ge Lan from China Europe Fund, with a return of 38.66% and a management scale close to 400 billion yuan [6][7]. Fund Management Scale Insights - Among female fund managers, 304 manage over 10 billion yuan, and 72 manage over 50 billion yuan [9]. - The top female fund manager by scale is Cai Kaer from Fu Guo Fund, with a return of 40.99% and a management scale of approximately 588 billion yuan [10][11]. Performance in Active Equity Funds - There are 346 female active equity fund managers, with the top 20 this year having a return threshold of 53.49% [13]. - Zhou Shanshan from交银施罗德基金 leads with a return of 93.45% [14][15]. Investment Focus - Zhou Encong focuses on innovative drugs and believes 2025 will be a pivotal year for the industry [6]. - Ge Lan's top holdings are in the biopharmaceutical sector, indicating a strategic focus on healthcare [7][8]. Conclusion - The article emphasizes the growing influence and success of female fund managers in the public fund industry, reflecting a shift in the investment landscape towards greater gender diversity and performance excellence [3][4].

Core Viewpoint - The significant stock price surge of药捷安康-B (02617.HK) is closely linked to its core product, Tinengotinib, which has received clinical approval for treating specific breast cancer types, indicating strong market potential and investor interest [1][2]. Company Overview -药捷安康-B's stock price increased by 131.26% at one point on September 12, closing at 192.5 HKD per share, with a market capitalization exceeding 70 billion HKD [1]. - The company went public on June 23, with an initial offering price of 13.15 HKD, and its stock price has risen over 18 times since then [1]. Product Details - Tinengotinib is a unique MTK inhibitor targeting FGFR/VEGFR, JAK, and Aurora kinases, aimed at treating various refractory solid tumors, including cholangiocarcinoma and breast cancer [2]. - It is the first and only FGFR inhibitor in the registration clinical stage for treating refractory cholangiocarcinoma, with significant clinical efficacy evidence for mCRPC [2]. Market Potential - The global cholangiocarcinoma drug market is projected to grow to 3.1 billion USD by 2026 and further to 5.4 billion USD by 2030 [2]. - In China, the cholangiocarcinoma drug market reached 2 billion RMB in 2022, expected to grow to 5.5 billion RMB by 2026 [2]. Financial Performance -药捷安康 has not yet approved any products for market, resulting in continuous financial losses, with reported losses of 252 million RMB in 2022, 343 million RMB in 2023, and 275 million RMB in 2024, totaling 870 million RMB over three years [3]. - As of June 30, 2025, the company had cash and cash equivalents of 449 million RMB, with a significant drop in revenue of 90.4% year-on-year [3]. Competitive Landscape - The core product faces competition from other FGFR-targeting MTK inhibitors, including one that has already received FDA approval [3].